Roche to Acquire Carmot Therapeutics for ~$3.1B
- Roche announces the acquisition of Carmot Therapeutics providing access to Carmot's portfolio, incl. CT-388 & CT-996, offering treatments for obesity in patients with & without diabetes
- Under the agreement Carmot is qualified to receive an up front of $2.7B in cash & with potential milestone payments of up to $400M. Moreover, Roche gains access to Carmot's R&D assets, incl. clinical and pre-clinical portfolios. The transaction is expected to close in Q1’24
- Upon finalizing the agreement, Roche will secure exclusive rights to Carmot's innovative Chemotype Evolution discovery platform, strengthening Roche's R&D capabilities & expanding its portfolio in cardiovascular and metabolic diseases
Ref: Globe Newswire | Image: Roche
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at firstname.lastname@example.org.